Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Date 2025-06-11 09:31:22 (MENAFN - EIN Presswire) Northeast Health Services offers SPRAVATO®, FDA-approved nasal spray for treatment-resistant depression, providing fast, effective symptom relief.

None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

While Spravato ® is FDA-cleared for TRD, fewer than 15% of IV-ketamine clinics currently offer it, largely due to REMS, DEA, and payer-compliance hurdles. Program Highlights ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Since Spravato is FDA-approved, it’s covered by most insurance companies. IV ketamine, on the other hand, is generally not covered.

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...